Suspended
PETChidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma, a Multicentric, Single Arm, Open Label Phase II Clinical Trial
What is being tested
Chidamide
Drug
Who is being recruted
Lymphadenopathy+4
+ Hemic and Lymphatic Diseases
+ Immunoblastic Lymphadenopathy
From 18 to 75 Years
+24 Eligibility Criteria
How is the trial designed
Treatment Study
Phase 2
Interventional
Study Start: March 2017
Summary
Principal SponsorQingdao University
Study ContactHongwei Xue, MD. PhD
Last updated: January 27, 2026Sourced from a government-validated database.Claim as a partner
Study start date: March 1, 2017
Actual date on which the first participant was enrolled.Patients enrolled in the trial would be given prednisone, etoposide, thalidomide and Chidamide, and the response and side effects are observed and documented.
Official TitleChidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma, a Multicentric, Single Arm, Open Label Phase II Clinical Trial
Principal SponsorQingdao University
Study ContactHongwei Xue, MD. PhD
Last updated: January 27, 2026Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
30 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.From 18 to 75 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
LymphadenopathyHemic and Lymphatic DiseasesImmunoblastic LymphadenopathyImmune System DiseasesImmunoproliferative DisordersLymphatic DiseasesLymphoproliferative Disorders
Criteria
10 inclusion criteria required to participate
Pathologically diagnosed as angioimmunoblastic T cell lymphoma (diagnosed by pathologic department in IIIA hospitals or verified by certified institutions), immunohistochemistry should include: CD3, CD4, CD8, CD20, CD10, CD21, CD35, Bcl6, CXCL13, EBER, PD-1, Ki67.
At least on measurable focus (≥1.0*1.0cm by imaging), or at least one evaluable focus;
Age 18-75 years, both male and female;
ECOG 0-2, KPS≥ 70points;
Show More Criteria
14 exclusion criteria prevent from participating
Women during pregnancy or lactation, and fertile women that are not willing to take contraceptive measurements;
Patients with other malignant tumors simultaneously that have not been effectively controlled;
Patients with history of using HDAC inhibitors;
Patients who are allergic to medicine used in the trial, or have metabolic disorders toward these medicine;
Show More Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Treatment Groups
Study Objectives
One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalIn this group, patients will be given prednisone 100mg,qd,d1-5; etoposide 100mg,qd,d1-5; thalidomide 100mg,qn,d1-14; Chidamide 30mg,biw;
Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Recruiting
The Affiliated Hospital of Qingdao University
Qingdao, ChinaOpen The Affiliated Hospital of Qingdao University in Google MapsSuspendedOne Study Center